Neuraltus' NP001 fails Phase II for ALS

Neuraltus Pharmaceuticals Inc. (San Bruno, Calif.) said NP001 missed the primary and secondary endpoints in a Phase II trial to treat amyotrophic

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE